- Home
- ATLO vs VIGL Comparison
ATLO vs VIGL Comparison
Compare ATLO & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLO
- VIGL
- Stock Information
- Founded
- ATLO 1903
- VIGL 2020
- Country
- ATLO United States
- VIGL United States
- Employees
- ATLO N/A
- VIGL N/A
- Industry
- ATLO Major Banks
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ATLO Finance
- VIGL Health Care
- Exchange
- ATLO Nasdaq
- VIGL Nasdaq
- Market Cap
- ATLO 174.1M
- VIGL 148.7M
- IPO Year
- ATLO N/A
- VIGL 2022
- Fundamental
- Price
- ATLO $18.55
- VIGL $3.74
- Analyst Decision
- ATLO
- VIGL Buy
- Analyst Count
- ATLO 0
- VIGL 5
- Target Price
- ATLO N/A
- VIGL $16.60
- AVG Volume (30 Days)
- ATLO 14.9K
- VIGL 112.5K
- Earning Date
- ATLO 10-18-2024
- VIGL 08-13-2024
- Dividend Yield
- ATLO 5.53%
- VIGL N/A
- EPS Growth
- ATLO N/A
- VIGL N/A
- EPS
- ATLO 1.06
- VIGL N/A
- Revenue
- ATLO $51,275,000.00
- VIGL N/A
- Revenue This Year
- ATLO N/A
- VIGL N/A
- Revenue Next Year
- ATLO N/A
- VIGL N/A
- P/E Ratio
- ATLO $17.20
- VIGL N/A
- Revenue Growth
- ATLO N/A
- VIGL N/A
- 52 Week Low
- ATLO $15.01
- VIGL $2.47
- 52 Week High
- ATLO $22.50
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- ATLO 47.95
- VIGL 53.60
- Support Level
- ATLO $17.65
- VIGL $3.66
- Resistance Level
- ATLO $18.53
- VIGL $4.03
- Average True Range (ATR)
- ATLO 0.56
- VIGL 0.28
- MACD
- ATLO 0.07
- VIGL 0.05
- Stochastic Oscillator
- ATLO 67.46
- VIGL 65.06
About ATLO Ames National Corporation
Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.